GlobeNewswire Inc | Jul 27, 2021 02:00AM EDT

July 27, 2021

LONDON and RALEIGH, N.C., July 27, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (Verona Pharma), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Pharm. D., President and Chief Executive Officer, will present at the following virtual investor conferences in August 2021:

BTIG Virtual Biotechnology Conference Date: Monday, August 9Time: 1:30 PM EDT / 6:30 PM BST

12th Annual Wedbush PacGrow Healthcare Virtual Conference Date: Wednesday, August 11Time: 3:30 PM EDT / 8:30 PM BSTPanel: Breathless and Under Pressure Innovative Inhaled Treatments For Respiratory Diseases

41st Annual Canaccord Genuity Growth Conference Date: Thursday, August 12 Time: 11:00 AM EDT / 4:00 PM BST

A webcast of the Canaccord fireside chat will be available for 90 days on the Events and Presentations link on the Investors page of the Companys website, www.veronapharma.com.

US Tel: +1-833-417-0262Verona Pharma plc UK Tel: +44 (0)203 283 4200Victoria Stewart, Director of Investor Relations and info@veronapharma.comCommunications Argot Partners Tel: +1-212-600-1902(US Investor Enquiries) verona@argotpartners.comKimberly Minarovich / Michael Barron Optimum Strategic Communications Tel: +44 (0)203 950 9144(International Media and European Investor Enquiries) verona@optimumcomms.comMary Clark / Karl Hard / Elakiya Rangarajah

About Verona Pharma

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. If successfully developed and approved, Verona Pharmas product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. The Company is evaluating nebulized ensifentrine in its Phase 3 clinical program ENHANCE (Ensifentrine as a Novel inHAled Nebulized COPD thErapy) for COPD maintenance treatment. Two additional formulations of ensifentrine are in Phase 2 development for the treatment of COPD: dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). Ensifentrine has potential applications in cystic fibrosis, asthma and other respiratory diseases. For more information, please visit www.veronapharma.com.